Evaluating the effect of sildenafil on the prevention of Anthracyclines induced acute cardiotoxicity
Phase 3
Recruiting
- Conditions
- .
- Registration Number
- IRCT20180506039554N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Having Breast cancer or Non.hojkin lymphoma
Don,t usage of radiotherapy as a part of cancer treatment
Exclusion Criteria
History of CAD
History of CHF
History of severe valvular heart disease
Usage of nitrate for any causes
Having severe chronic disease such as renal failure,liver failure and autoimmune diseases
Concomitant usage of Betablocker,ACE,Statins
Systolic BP < 100
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method V Ejection fraction and diastolic function of the heart. Timepoint: Before and after 6 dose of chemotherapy with anthracyclin. Method of measurement: Calculate Lv Ejection fraction with 3D Echocardiography and diatolic function with speckled tracking.
- Secondary Outcome Measures
Name Time Method